Home » Stocks » INM

InMed Pharmaceuticals, Inc. (INM)

InMed Pharmaceuticals will go public soon, but the exact IPO date is still unknown.
Stock Price: $4.13
Confirmed IPO price

Stock Price Chart

Key Info

Market Cap 31.56M
Revenue (ttm) n/a
Net Income (ttm) -8.94M
Shares Out 7.64M
EPS (ttm) -1.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

More Stats

Market Cap 31.56M
Enterprise Value 25.71M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 7.64M
Float n/a
EPS (basic) n/a
EPS (diluted) -1.17
FCF / Share -0.97
Dividend n/a
Dividend Yield n/a
Earnings Yield -28.32%
FCF Yield -23.50%
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio -4.26
PS Ratio n/a
PB Ratio 5.37
Revenue n/a
Operating Income -9.15M
Net Income -8.94M
Free Cash Flow -7.42M
Net Cash 5.85M
Net Cash / Share 0.77
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-9.15-9.54
Net Income-8.94-9.25
Shares Outstanding5.225.19
Earnings Per Share-1.71-1.78
Operating Cash Flow-7.37-6.62
Capital Expenditures-0.04-0.03
Free Cash Flow-7.42-6.65
Cash & Equivalents5.8513.78
Net Cash / Debt5.8513.78
Book Value5.8814.24
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name InMed Pharmaceuticals, Inc.
Country Canada
CEO Eric A. Adams

Stock Information

Ticker Symbol INM
Stock Exchange NASDAQ
Industry Biotechnology
Unique Identifier NASDAQ: INM
IPO Date Pending


InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based prescription drug products targeting treatments for diseases with high unmet medical needs in a range of disease categories including dermatology and ocular diseases, among others. We work exclusively with non-plant-derived (synthetically manufactured), highly purified individual cannabinoid compounds. In parallel to our therapeutic programs, we are developing an integrated cannabinoid manufacturing technology to facilitate access to rare cannabinoids that are otherwise not available at commercial scale and low cost. Our goal is to be a leader in bringing cannabinoid-based therapies to patients who may benefit from them. To accomplish this goal, we have assembled a highly skilled group of individuals with extensive experience in all facets of pharmaceutical research and development, drug formulation, clinical trial execution, regulatory submissions, pharmaceutical commercialization, company and capital formation, business development, legal, and corporate governance. We are focused on bringing strict scientific discipline to the field of cannabinoid medicine to unlock the full potential of this class of drugs.